title: Ventilator-associated pneumonia, liver disease and oral chlorhexldine.
abstract: As part of the ventilator care bundle, the Department of Health (DH) in the U.K. recommends the use of chlorhexidine (CHX) for oral care to prevent the occurrence of ventilator-associated pneumonia (VAP) in all mechanically ventilated patients. Due to the heterogenous nature of this population, however, it is important to consider whether such recommendations are also relevant to specific critical care patient population groups. This article reviews the available scientific evidence on the use of CHX in the prevention of VAP, with a focus on critically ill mechanically ventilated patients who have liver dysfunction. Findings will be discussed with reference to the wider research literature in order to make recommendations for future practice.
authors.affiliation: Liver Intensive Therapy Unit, King's College Hospital, London.
authors.forename: Titilayo O
authors.initials: TO
authors.lastname: Oshodi
authors.forename: Suzanne
authors.initials: S
authors.lastname: Bench
mesh_terms: D000284:Administration, Oral; D002710:Chlorhexidine / Q000009:adverse effects*; D004739:England; D006801:Humans; D008107:Liver Diseases / Q000150:complications*; D053717:Pneumonia, Ventilator-Associated / Q000139:chemically induced / Q000150:complications*
chemical_list: D002710:Chlorhexidine